EyeGate Pharmaceuticals

EyeGate Pharmaceuticals EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of EyeGate Pharmaceuticals (EYEG) as of Nov 2, 2026 is -2.03. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -1.48 — a change of 37.50% (lower).

EV/FCF

-2.03

YoY

37.50%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of EyeGate Pharmaceuticals is 2020 -2.03 . EV/FCF (Enterprise Value to Free Cash Flow) of EyeGate Pharmaceuticals was 2019 -1.48 . It decreases by 37.50% lower compared to the previous year.

The EyeGate Pharmaceuticals EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2014
-19.85 USD
Jan 1, 2015
-1.67 USD
Jan 1, 2016
-1.45 USD
Jan 1, 2017
-1.23 USD
Jan 1, 2018
-0.70 USD
Jan 1, 2019
-1.48 USD
Jan 1, 2020
-2.03 USD
The EyeGate Pharmaceuticals EV/FCF history
YEAREV/FCFYoY
-2.03+37.50%
-1.48+109.88%
-0.70-42.79%
-1.23-15.08%
-1.45-13.03%
-1.67-91.61%
-19.85—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

EyeGate Pharmaceuticals Stock analysis

What does EyeGate Pharmaceuticals do? EyeGate Pharmaceuticals Inc. is a US pharmaceutical company specializing in the development of ophthalmology products. It was founded in 1998 and is headquartered in Waltham, Massachusetts. The company aims to meet the need for safe and effective therapies for the treatment of eye diseases. Its business model focuses on the development and commercialization of products that enable faster and more effective treatment of eye diseases. The company has two main divisions. The first division includes iontophoretic drug delivery technologies used for the treatment of eye diseases. Iontophoresis is a process in which electric currents are used to transport medications through the skin and into the eyes. EyeGate Pharmaceuticals has developed the EyeGate® II Delivery System technology, which allows for non-invasive, painless, and safe administration of medications into the eye. The EyeGate II Delivery System can be used for the treatment of inflammation, pain, and infections in the eye area. The second division is the development of drugs used for the treatment of eye diseases. EyeGate Pharmaceuticals has several clinical programs in development, including EGP-437, a steroid-free corticosteroid used for the treatment of inflammation of the anterior eye segment. EGP-437 is currently being tested in two clinical trials to demonstrate its efficacy and safety in the treatment of pain and inflammation in the eye. In addition, the company has developed the drug EGP-259 for the treatment of dry eye. EyeGate Pharmaceuticals has previously entered into several partnerships with other companies to further develop and commercialize its technology platform. In 2019, the company entered into a partnership with Valeant Pharmaceuticals International, Inc. to advance the marketing of EGP-437 in the United States. EyeGate Pharmaceuticals aims to continue growing and expanding its presence in the field of ophthalmology in the coming years. The company is working on the development of new products and technologies that enable it to respond to the changing needs and challenges in ophthalmology. Overall, EyeGate Pharmaceuticals is committed to developing and marketing innovative and effective technologies and drugs for the treatment of eye diseases. The company is well positioned to grow in a rapidly evolving market and make a significant contribution to improving the health and quality of life of millions of people worldwide. EyeGate Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EyeGate Pharmaceuticals stock

EV/FCF (Enterprise Value to Free Cash Flow) of EyeGate Pharmaceuticals is -2.03 in 2020.

EV/FCF (Enterprise Value to Free Cash Flow) of EyeGate Pharmaceuticals changed from -1.48 to -2.03, representing a 37.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) EyeGate Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s EyeGate Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — EyeGate Pharmaceuticals

All Key Metrics — EyeGate Pharmaceuticals